Links:
The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.
Many patients do have psoriasis before onset of symptoms. This question can either be explored retrospectively using existing data or
Read Article
Links:
Dr. Jack Cush talks on education, engagement and the challenge of speaking up, if not first!
Read Article
B-cells play a major role in the pathogenesis of primary Sjogren’s syndrome (pSS) through antibody-dependent and antibody-independent functions, as well as evident by progression to B-cell malignancies/lymphoma. Hence, targeting B-cell is attractive. Despite efficacy of B-cell depleting therapy
Read Article
Links:
It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.
Read Article
Subtle early bony changes in inflammatory arthritis can be hard even for experienced rheumatologists to interpret, even though they have traditionally been considered to become disease-defining as they progress. As computational techniques have become more sophisticated and more accessible,
Read Article
Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. The current study of Tillett et al (OP0231) assessed comorbidities and patient characteristics comparing
Read Article
Links:
Links:
Links:
All of us are extremely cautious with lupus patients when it comes to pregnancy. Presentation 6888 (Common issues in pregnancy management in lupus and anti-phospholipid syndrome by Dr. Rebecca Fischer-Betz) was an excellent overview of our current approach to lupus and pregnancy.
Read Article
Links:
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Read Article
Links:
Links:
Links:
Despite being relatively common and frequently severe, RA-ILD has been a neglected area of research and indeed of clinical management in RA. In recent years we finally seem to have started making some progress in this area and this momentum has continued with a several interesting abstracts at
Read Article
RheumNow faculty reporters scoured the Posters and Presentations from virtual EULAR 2021. Several of these are novel enough to be worthy of your consideration. Below is the list of the six most often retweeted abstracts from Day 1.
Read Article
Links:
Links:
An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351). Markers of pathways
Read Article
Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response.
Read Article
Cutaneous lupus erythematosus (CLE) consists of a wide range of dermatologic manifestations seen in people with or without systemic lupus erythematosus (SLE). CLE can be categorised into LE-specific lesions, i.e. acute CLE (ACLE), subacute CLE (SCLE) and chronic CLE (CCLE), and nonspecific LE
Read Article
Since the COVID vaccine rollout, more people have been eligible to receive the vaccine. However, not everyone chooses to get one. I have heard many reasons (aka excuses) from my patients who are vaccine hesitant.
Most come from people who are highly intelligent, and claimed that they will receive the vaccine but not yet. While I am not trying to force people to get vaccinated, I wanted to hear their side of the story and also ask that they hear mine.
Read Post
